Kongressthemen The development of mono- and bivalent degraders continues to gain traction, but biopharma faces challenges in rapidly discovering, validating, and utilizing novel E3 ligases. This leaves therapeutic opportunities untapped due to obstacles in ligase screening, structural characterization, and assaying therapeutic efficacy.
